Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira also has collaborative partnerships with leading companies in the RNAi field.
Nov 13, 2013 at 1:30 PM PT
Tekmira Provides Corporate Update and Announces Third Quarter Results
Oct 24, 2013
1st International mRNA Health Conference